|
EP0041313B1
(de)
|
1980-04-03 |
1990-09-12 |
Biogen, Inc. |
DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem menschlichen Fibroblast-Interferon
|
|
UA39161C2
(uk)
*
|
1984-07-06 |
2001-06-15 |
Новартіс Аг |
Рекомбінантний білок gm-csf для збільшення продукції гранулоцитів і макрофагів у пацієнтів, вектор і кднк, що його кодують
|
|
JPS61227526A
(ja)
*
|
1984-07-25 |
1986-10-09 |
Chugai Pharmaceut Co Ltd |
新規なコロニー刺激因子
|
|
UA29377C2
(uk)
*
|
1984-09-19 |
2000-11-15 |
Новартіс Аг |
Спосіб отримання білка з активністю колонієстимулювального фактора гранулоцитів та макрофагів(gm-csf) приматів
|
|
JP3038348B2
(ja)
*
|
1984-11-20 |
2000-05-08 |
シェーリング コーポレイション |
ヒト顆粒状、マクロファージおよび好酸球の細胞増殖因子活性を示すポリペプチドをコードするｃＤＮＡクローン
|
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
|
DE3681551D1
(de)
*
|
1985-09-30 |
1991-10-24 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granulozyten-colony stimulierender faktor.
|
|
JPH0618778B2
(ja)
*
|
1985-10-04 |
1994-03-16 |
中外製薬株式会社 |
白血球減少症治療剤
|
|
US5298603A
(en)
*
|
1985-12-21 |
1994-03-29 |
Hoechst Aktiengesellschaft |
GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
|
|
DE3545568A1
(de)
*
|
1985-12-21 |
1987-07-16 |
Hoechst Ag |
Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
|
|
EP0232707A1
(de)
*
|
1986-01-09 |
1987-08-19 |
Ajinomoto Co., Inc. |
Menschlicher Faktor zur Steigerung des hämatopoietischen Zellwachstums
|
|
US5106733A
(en)
*
|
1987-06-25 |
1992-04-21 |
Immunex Corporation |
Bovine granulocyte-macrophage colony stimulating factor
|
|
EP0413721A4
(en)
*
|
1988-04-21 |
1991-11-13 |
Medvet Science Pty. Ltd. |
Human gm-csf variants
|
|
EP0486572B1
(de)
*
|
1989-08-11 |
1998-01-07 |
Amrad Corporation Limited |
Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate
|
|
DK0814154T3
(da)
|
1993-09-15 |
2009-08-31 |
Novartis Vaccines & Diagnostic |
Rekombinante alfavirusvektorer
|
|
EP0791061A4
(de)
*
|
1994-03-04 |
1998-07-15 |
Ludwig Inst Cancer Res |
Tiere mit gezielter genunterbrechung
|
|
AU2800797A
(en)
|
1996-04-05 |
1997-10-29 |
Chiron Corporation |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
|
EP2298900A1
(de)
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
|
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
ES2297889T3
(es)
*
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
US7507705B2
(en)
|
1997-10-02 |
2009-03-24 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
ATE446767T1
(de)
*
|
1999-02-12 |
2009-11-15 |
Univ Washington |
Gm-csf zur behandlung von morbus crohn
|
|
US6911204B2
(en)
|
2000-08-11 |
2005-06-28 |
Favrille, Inc. |
Method and composition for altering a B cell mediated pathology
|
|
HK1052314A1
(zh)
*
|
2000-08-11 |
2003-09-11 |
Favrille, Inc. |
改变t细胞介导的病理的方法和组合物
|
|
EP2280074A3
(de)
|
2001-07-05 |
2011-06-22 |
Novartis Vaccines and Diagnostics, Inc. |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
|
EP1411770A4
(de)
|
2001-07-05 |
2006-05-10 |
Chiron Corp |
Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
|
|
JP2006500905A
(ja)
|
2002-02-13 |
2006-01-12 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
ヒト化ｇｍ−ｃｓｆ抗体
|
|
EP2339010B1
(de)
|
2002-05-01 |
2017-04-12 |
Miltenyi Biotec Technology, Inc. |
Gegenüber Komplement-Inaktivierung resistente Lentivirusvektorpartikel
|
|
GB0210741D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Medical Res Council |
Methods of therapy
|
|
GB0224415D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Medical Res Council |
Compositions
|
|
US8541003B2
(en)
|
2003-06-20 |
2013-09-24 |
Protein Sciences Corporation |
Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
|
|
CN101072585A
(zh)
|
2004-11-01 |
2007-11-14 |
诺华疫苗和诊断公司 |
产生免疫应答的组合方法
|
|
GB0524103D0
(en)
*
|
2005-11-26 |
2006-01-04 |
Medical Res Council |
Healing
|
|
US7741450B2
(en)
|
2006-02-08 |
2010-06-22 |
Morphotek Inc. |
Antibodies to GM-CSF
|
|
WO2007137300A2
(en)
|
2006-05-23 |
2007-11-29 |
Bellicum Pharmaceuticals, Inc. |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
|
CA2777400C
(en)
|
2009-10-12 |
2018-11-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Granulysin in immunotherapy
|
|
WO2012093258A2
(en)
|
2011-01-05 |
2012-07-12 |
Imperial Innovations Limited |
Treatment and screening
|
|
EP2870238A4
(de)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
Zusammensetzungen und verfahren in zusammenhang mit viralen impfstoffen
|
|
CA2996762A1
(en)
|
2015-08-31 |
2017-03-09 |
Technovax, Inc. |
Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
|
|
US10612005B2
(en)
|
2016-01-08 |
2020-04-07 |
Replimune Limited |
Modified oncolytic virus
|
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
|
KR102718353B1
(ko)
|
2016-10-17 |
2024-10-15 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 바이러스 레플리콘 시스템 및 그의 용도
|
|
CA3045650A1
(en)
|
2016-12-05 |
2018-06-14 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for enhancing gene expression
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
|
JP7494117B2
(ja)
|
2018-01-19 |
2024-06-03 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
組換えレプリコン系を使用する免疫応答の誘導および増強
|
|
WO2020076775A1
(en)
|
2018-10-08 |
2020-04-16 |
Janssen Pharmaceuticals, Inc. |
Alphavirus-based replicons for administration of biotherapeutics
|